GRFS: Grifols SA insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
166 institutions reported holding $1.01B of Grifols SA on Form 13F (188 the quarter before). 15 opened a new position and 38 sold out. Shares held by institutions: -1%.
| Largest holders | Shares | Value |
|---|---|---|
| BRANDES INVESTMENT PARTNERS, LP | 37,816,285 | $267.74M |
| Capital World Investors | 22,911,656 | $162.21M |
| Permian Investment Partners, LP | 19,740,679 | $139.76M |
| Black Creek Investment Management Inc. | 7,682,055 | $54.39M |
| BANK OF AMERICA CORP /DE/ | 6,550,337 | $46.38M |
| MILLENNIUM MANAGEMENT LLC | 4,369,934 | $30.94M |
| Flat Footed LLC | 4,349,708 | $30.80M |
| Jupiter Topco LLC | 2,958,981 | $20.91M |
| ARMISTICE CAPITAL, LLC | 2,936,000 | $20.79M |
| MORGAN STANLEY | 2,661,180 | $18.84M |
Clinical trial readouts
1 Phase 2 or 3 trials by Grifols SA with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-09-30 (est.) | Alpha-1 15% | Alpha 1 Antitrypsin Deficiency | Phase 3 | 40 | Recruiting | NCT07555483 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.